🇺🇸 FDA
Patent

US 11208493

Internalizing human monoclonal antibodies targeting prostate and other cancer cells

granted A61KA61K47/6811A61K47/6829

Quick answer

US patent 11208493 (Internalizing human monoclonal antibodies targeting prostate and other cancer cells) held by The Regents of the University of California expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/6811, A61K47/6829, A61K47/6849, A61K47/6869